Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Leonabio Inc
LONA
$10.07 (+ $0.45 + 4.68%)
Last updated: 2026-05-21 23:56 UTC
About the Company
Athira Pharma Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company's primary aim is to discover and commercialize novel therapeutics targeting Alzheimer's disease and other neurological disorders. Athira Pharma's lead product candidate is designed to help repair neuronal damage, potentially offering a regenerative approach to these debilitating conditions. The company employs cutting-edge research in protein therapeutics and uses proprietary small molecule therapeutics to improve cognitive function by targeting mechanisms that facilitate neural health and maintenance. Based in the biopharmaceutical innovation hub of the United States, Athira Pharma plays a significant role in the biotech sector, particularly in the neurology and Alzheimer's treatment market. It operates within a crucial segment of the healthcare industry, addressing some of the most challenging and urgent unmet medical needs. The company's initiatives, driven by scientific research and development, underline its commitment to transforming the treatment landscape for neurodegenerative diseases, contributing to the broader goals of the healthcare and life sciences industries.
Price History
Latest News for LONA
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 202
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
Seasoned leaders bring deep experience in oncology and neurology drug development, corporate strategy, operational execution, and capital markets as company continues to advance clinical pipelineBOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter B. Sil
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data Expected in 2H27 Webinar Event on Wednesday, April 29, 2026, at 12:00 p.m. ET BOTHELL, Wash., April 23, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data
Results showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancerBOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, attended the American Association for Cancer Research Annual Meeting 2026 (AACR26), where ind
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing of Common Stock and Warrants with Cash-Exercisable Warrants Potentially Providing up to an Additional $146 Million to Support Development of Lasofoxifene Through Key Clinical and Regulatory Milestones E
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
Brings more than 25 years of biopharma business development and corporate strategy expertiseBOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio’s business development strategy and execution, with responsibility for